Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.71 |
| ▸ | KDR | P35968 | 10/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733870 | 0.86 | KDR (0.72) | TGFBR1KDRMAPK14 | |
| SCHEMBL20074591 | 0.83 | TGFBR1 (1.00) | TGFBR1KDRMAPK14 | |
| SCHEMBL20074449 | 0.83 | TGFBR1 (1.00) | TGFBR1KDRMAPK14 | |
| SCHEMBL20074451 | 0.83 | TGFBR1 (1.00) | TGFBR1KDRMAPK14 | |
| SCHEMBL21734147 | 0.83 | TGFBR1 (0.71) | TGFBR1KDRMAPK14 | |
| SCHEMBL21277860 | 0.80 | TGFBR1 (0.66) | TGFBR1KDRMAPK14MAP4K4TNIK | |
| SCHEMBL21733939 | 0.72 | TGFBR1 (0.71) | TGFBR1KDRMAPK14 | |
| SCHEMBL20074639 | 0.69 | KDR (1.00) | TGFBR1KDRMAPK14 | |
| SCHEMBL20074632 | 0.69 | KDR (1.00) | TGFBR1KDRMAPK14 | |
| SCHEMBL20074530 | 0.69 | KDR (1.00) | TGFBR1KDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | TGFBR1, TGFB2, TGFB1 | TGFBR1 1/4885KDR 227/4885MAPK14 1887/4885 |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TGFBR1, TGFB2, TGFB1 | TGFBR1 1/4885KDR 227/4885MAPK14 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.